Septerna (NASDAQ:SEPN) Stock Price Down 5.9% on Insider Selling

Septerna, Inc. (NASDAQ:SEPN)’s stock price traded down 5.9% during trading on Friday after an insider sold shares in the company. The company traded as low as $26.15 and last traded at $25.4950. 11,134 shares changed hands during trading, a decline of 96% from the average session volume of 291,271 shares. The stock had previously closed at $27.08.

Specifically, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the transaction, the chief operating officer owned 174,209 shares in the company, valued at $5,046,834.73. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SEPN shares. JonesTrading started coverage on shares of Septerna in a research note on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price objective on the stock. Raymond James Financial began coverage on shares of Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price target on the stock. Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $18.00 to $28.00 in a research note on Friday, November 14th. Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. Finally, Zacks Research lowered Septerna from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.83.

Septerna Price Performance

The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -18.07 and a beta of 3.85. The stock has a fifty day moving average of $26.73 and a two-hundred day moving average of $21.71.

Hedge Funds Weigh In On Septerna

A number of hedge funds have recently made changes to their positions in SEPN. Woodline Partners LP lifted its stake in shares of Septerna by 94.2% in the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after acquiring an additional 282,585 shares during the period. Rhumbline Advisers raised its holdings in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after purchasing an additional 3,323 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after purchasing an additional 78,316 shares during the period. Intech Investment Management LLC bought a new stake in shares of Septerna in the 2nd quarter valued at $129,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Septerna by 116.7% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock worth $2,354,000 after buying an additional 119,953 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.